Sam Brusco, Associate Editor04.18.23
Neuspera Medical has gained U.S. Food and Drug Administration (FDA) clearance for its next-generation Neuspera ultra-miniaturized system. The system consists of a micro-implant that delivers peripheral nerve stimulation (PNS) through a wireless platform, including a wearable transmitter and iPad-based clinician programmer.
According to the company, the system is the first PNS device with an ultra-miniaturized option—75 times smaller than the smallest commercial implantable pulse generator. It can provide physicians the opportunity for deeper anatomical targets compared to current technologies.
"We look forward to bringing this innovative technology to physicians and patients in the U.S.," Steffen Hovard, CEO of Neuspera Medical told the press. "The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients' health and quality of life."
PNS is becoming an increasingly important treatment modality to manage chronic pain conditions. The market is expected to experience significant growth because of the growing prevalence of chronic pain, advances in implantable technology, and rising demand for alternative pain management therapies.
According to the company, the system is the first PNS device with an ultra-miniaturized option—75 times smaller than the smallest commercial implantable pulse generator. It can provide physicians the opportunity for deeper anatomical targets compared to current technologies.
"We look forward to bringing this innovative technology to physicians and patients in the U.S.," Steffen Hovard, CEO of Neuspera Medical told the press. "The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients' health and quality of life."
PNS is becoming an increasingly important treatment modality to manage chronic pain conditions. The market is expected to experience significant growth because of the growing prevalence of chronic pain, advances in implantable technology, and rising demand for alternative pain management therapies.